Last reviewed · How we verify
Intravenous amiodarone(1)
Intravenous amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to suppress abnormal electrical activity and restore normal heart rhythm.
Intravenous amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to suppress abnormal electrical activity and restore normal heart rhythm. Used for Acute conversion of atrial fibrillation to normal sinus rhythm, Suppression of life-threatening ventricular arrhythmias, Maintenance of normal sinus rhythm in patients with atrial fibrillation.
At a glance
| Generic name | Intravenous amiodarone(1) |
|---|---|
| Also known as | 24 hour amiodarone |
| Sponsor | Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud |
| Drug class | Class III antiarrhythmic agent |
| Target | Potassium channels, sodium channels, calcium channels, beta-adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiodarone is a Class III antiarrhythmic agent with properties of all four Vaughan-Williams classes. It prolongs the action potential duration and refractory period by blocking potassium channels, while also inhibiting sodium and calcium channels and beta-adrenergic receptors. This multi-channel blockade makes it effective for suppressing both atrial and ventricular arrhythmias.
Approved indications
- Acute conversion of atrial fibrillation to normal sinus rhythm
- Suppression of life-threatening ventricular arrhythmias
- Maintenance of normal sinus rhythm in patients with atrial fibrillation
Common side effects
- Hypotension
- Bradycardia
- Phlebitis at injection site
- Nausea
- Pulmonary toxicity (chronic use)
- Thyroid dysfunction (chronic use)
- Hepatotoxicity
Key clinical trials
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Rate, Rhythm or Risk Control for New-onset Supraventricular Arrhythmia During Septic Shock: a Randomized Controlled Trial (NA)
- Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia (PHASE3)
- Refralon Versus Amiodarone for Cardioversion of Paroxysmal Fibrillation and Atrial Flutter (PHASE4)
- Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation (PHASE4)
- Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery (PHASE3)
- Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: